Prognostic value of CD25 expression on lymphocytes and tumor cells in squamous-cell carcinoma of the head and neck

Cancer Biotherapy and Radiopharmaceuticals

Volumn 23, Issue 1, 2008, Pages 25-33

  Loose, David ^a   Signore, Alberto ^b,c   Bonanno, Elena ^d   Vermeersch, Hubert ^a   Dierckx, Rudi ^a,b   Deron, Philippe ^a   Van De Wiele, Christophe ^a,b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

CD25; Lymphocytes; Prognosis; Squamous cell carcinoma of the head and neck

Indexed keywords

ADULT; AGED; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FROZEN SECTION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPH NODES; LYMPHOCYTES; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 39749146990     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.0373     Document Type: Article

References (23)

1. Hoffmann TK, Whiteside TL, Bier H. Squamous-cell carcinoma of the head and neck. Principles and current concepts of immunotherapy. HNO 2005;53:285.
2. Boheim K, Denz H, Boheim C, Glassl H, Huber H. An immunohistologic study of the distribution and status of activation of head and neck tumor infiltrating leukocytes. Arch Otorhinolaryngol 1987;244:127.
3. Bourgeois C, Veiga-Fernandes H, Joret AM, Rocha B, Tanchot C. CD8 lethargy in the absence of CD4 help. Eur J Immunol 2002;32:2199.
4. + T-cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J Exp Med 1997;186:2057.
5. Bevan MJ. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004;4:595.
6. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850.
7. Greenberg PD. Adoptive T-cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991;49:281.
8. Cortesina G, Sacchi M, Galeazzi E, Johnson JT, Whiteside TL. Interleukin-2 receptors on squamous-cell carcinomas of the head and neck. Characterization and functional role. Acta Otolaryngol 1992;112:370.
9. Reichert TE, Nagashima S, Kashii Y, Stanson J, Gao G, Dou QP, Whiteside TL. Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression. Oncogene 2000;19:514.
10. Weidmann E, Sacchi M, Plaisance S, Heo DS, Yasumura S, Lin WC, Johnson JT, Herberman RB, Azzarone B, Whiteside TL. Receptors for interleukin-2 on human squamous-cell carcinoma cell lines and tumor in situ. Cancer Res 1992;52:5963.
11. Yasumura S, Lin W, Weidmann E, Hebda P, Whiteside T. Expression of interleukin-2 receptors on human carcinoma cell lines and tumor growth inhibition by interleukin-2. Int J Cancer 1994;59:225.
12. Snyderman CH, Heo DS, Chen K, Whiteside TL, Johnson JT. T-cell markers in tumor-infiltrating lymphocytes of head and neck cancer. Head Neck 1989;11:331.
13. + T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006;12:465.
14. + regulatory T-cells. Nat Immunol 2003;4:330.
15. Hori S, Nomura T, Sakaguchi S. Control of regulatory T-cell development by the transcription factor Foxp3. Science 2003;299:1057.
16. + regulatory T-cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531.
17. + suppressor T-cells: More questions than answers. Nat Rev Immunol 2002;2:389.
18. Balkwill F, Coussens LM. Cancer: An inflammatory link. Nature 2004;431:405.
19. + regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res 2005;65:3998.
20. Shevach E, Stephens G. The GITR-GITRL interaction: Costimulation or contrasuppression of regulatory activity. Nat Rev Immunol 2006;6:613.
21. + T-cells. Cell Mol Immunol 2006;3:189.
22. Kuhn DJ, Smith DM, Pross S, Whiteside TL, Dou QP. Overexpression of interleukin-2 receptor alpha in a human squamous-cell carcinoma of the head and neck cell line is associated with increased proliferation, drug resistance, and transforming ability. J Cell Biochem 2003;89:824.
23. Sacchi M, Snyderman CH, Heo DS, Johnson JT, d'Amico F, Herberman RB, Whiteside TL. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin-2. Cancer Res 1990;50:3113.